CENTER FOR SINGLE PHOTO-EMITTING CANCER IMAGING AGENTS:

单一光发射癌症成像剂中心：

• 批准号: 6377896
• 负责人: Wynn A Volkert
• 金额: $ 40万
• 依托单位: UNIVERSITY OF MISSOURI-COLUMBIA
• 依托单位国家: 美国
• 财政年份: 2000
• 资助国家: 美国
• 起止时间: 2000-04-14 至 2003-03-31
• 项目状态: 已结题
• 来源: https://reporter.nih.gov/project-details/6377896
• 关键词: SCID mouse; angiogenesis; bacterial virus; bioimaging /biomedical imaging; biomedical resource; breast neoplasms; chemical conjugate; colorectal neoplasms; dogs; imaging /visualization /scanning; indium; iodine; molecular oncology; prostate neoplasms; protooncogene; radionuclides; radiopharmacology; radiotracer; technetium; tissue inhibitor of metalloproteinases

The University of Missouri-Columbia (MU) is applying for a P-20 Pre-In vivo Cellular and Molecular Imaging (PRE-ICMIC) planning grant. The research projects that will be supported by this grant focus on the identification and development of single photon emitting site-directed in vivo targeting biomolecule- conjugates directed to cell surface receptor antigens and angiogenesis markers with high specificity. Molecular biological techniques form the primary approach for the design and generation of new cancer targeting vectors (incl., phage display, combinatorial chemistry and SPPS). The PRE-ICMIC will provide essential support to catalyze the formation of interdisciplinary research teams which are composed of scientists that combine expertise in molecular biology, chemistry, radiopharmaceutical chemistry, comparative oncology, pharmacology, tumor biology and pathology, and Nuclear Medicine. The research programs developed as part of this PRE-ICMIC are focussed on development of Tc-99m- and In-111-labeled diagnostic imaging agents. The organizational structure and Core facilities that will be instituted will support and promote cross-disciplinary research activities. This planning grant will be a critical milestone for establishment of a ICMIC at MU and will facilitate expansion and enhance the scope and quality of the radiopharmaceutical sciences research related to development of novel, highly specific cancer targeting imaging agents at this institution. At the completion of this grant, MU plans to be positioned to successfully apply for a P-50 ICMIC.

密苏里大学哥伦比亚大学（MU）正在申请P-20前体内细胞和分子成像（ICMIC前）计划赠款。 该赠款将支持的研究项目重点是鉴定和开发单个光子发射位点，以靶向生物分子的分子偶联物，该研究针对细胞表面受体抗原和具有较高特异性的血管生成标志物。 分子生物技术构成了设计和生成新的癌症靶向载体（包括，噬菌体显示，组合化学和SPP）的主要方法。 ICMIC将提供基本的支持，以促进由科学家组成的跨学科研究团队的形成，这些研究团队结合了分子生物学，化学，放射性药物化学，比较肿瘤学，药理学，肿瘤生物学和病理学和病理学和核医学方面的专业知识。 作为此前ICMIC的一部分开发的研究计划的重点是开发TC-99M和IN-111标记的诊断成像剂。 将建立的组织结构和核心设施将支持和促进跨学科研究活动。 该计划赠款将是在MU建立ICMIC的关键里程碑，并将促进扩展和增强与该机构中新型，高度特定的癌症靶向成像剂的开发有关的放射性药物科学研究的范围和质量。 本赠款完成后，MU计划将其定位为成功申请P-50 ICMIC。